This site is intended for UK Healthcare professionals only

This site is intended for UK healthcare professionals only



22 Dec, 2022

British Menopause Society responds to HRT prescribing issue

The British Menopause Society has published a statement following the publication of articles in The Daily Telegraph and the Sun on Monday 19 December, relating to the prescribing of higher than licensed doses of oestrogen in HRT.

The British Menopause Society is aware that high doses of oestrogen are being provided routinely to women in some clinics. This could increase the risk of abnormal bleeding requiring investigation, endometrial hyperplasia and endometrial cancer.

Most women will respond to licensed doses, and it is important to make women aware that some symptoms, such as low mood and anxiety may have other causes and may require other additional treatments. This is safer than increasing the amount of oestrogen provided (outside of license). NICE NG23 recommends using the lowest dose of oestrogen that controls menopausal symptoms. That does not mean that the dose should be increased out of license or that different forms of oestrogen should be added together to control symptoms. In the event of a significant event occurring (such as endometrial hyperplasia or cancer) in women using different formulations of oestrogen, outside of license, the prescribing clinicians are responsible for having put patient safety at risk.

There is no recommended systemic level of oestrogen in association with use of HRT and response to treatment with HRT should be based on symptom control. Checking serum oestradiol levels is influenced by many factors including the timing of the dose and type of assay and cannot be assumed to be indicative of levels over a 24-hour period.

Routine testing of oestrogen levels is unnecessary and is associated with an unnecessary cost for patients in the private sector.

Higher doses of oestrogen require a higher dose of progestogen to ensure adequate endometrial protection (Tools for Clinicians: Progestogens and endometrial protection).

The British Menopause Society educates and supports healthcare professionals to ensure that women who require HRT can access treatment safely. The necessary guidelines are available on the website for all healthcare professionals and are not restricted to members.


Latest news

PCWHF Year in Review 2023

Thank you for being part of our wonderful community for another year. Throughout 2023, the Primary Care Women's Health Forum is proud to have supported clinicians across the UK to ensure the very best patient care is delivered. As the year draws to a close, let's take...

NICE publishes updated draft menopause guideline

NICE has published its updated menopause guideline for public consultation. The draft guideline lays out clearly the risks and benefits of taking HRT that can be used to help people when they are discussing whether to start HRT with their clinician. Detailed tables...

Government survey seeks women’s views on reproductive health

Women in England are being encouraged to help shape reproductive health policy by sharing their experiences, in a new government survey. Delivering on a key commitment in the Women’s Health Strategy, the Women’s Reproductive Health Survey seeks women’s views across...

HFEA ‘State of the Fertility Sector’ report

The Human Fertilisation and Embryology Authority’s (HFEA) State of the Fertility Sector 2022/23 report reveals that out of the almost 100,000 treatment and storage cycles which took place, more than 99% were conducted without any incidents occurring. The annual report...